Background: Gastric cancer is the most common cancer in Oman and a leading cause of cancer death. The variation in survival rates between countries and ethnic groups has been attributed to early detection policies, differences in clinicopathological features, treatment approaches, and biological characteristics. There were no previous reports on gastric cancer from Oman and very few studies on Asian Arabs. Aim: To evaluate the impact of clinicopathological and treatment variables on the survival prospects of Omani Arab patients diagnosed with gastric cancer. Methods: The medical records of 339 Omani Arab patients diagnosed with invasive gastric adenocarcinoma during the period 1993–2004 were retrospectively reviewed. The relative importance of clinicopathological features and surgical and medical treatments were assessed using univariate and multivariate analyses. Results: Most patients had distal ulcerating-type gastric cancer and presented at advanced stages. The median survival time for the entire cohort was 12 months (95% CI 9.7–14.4) with a 5-year overall survival rate of 16.7%. On univariate analysis of 237 patients who underwent surgical resection, the following positive prognostic factors emerged as significant: early overall TNM stage, early T stage, negative lymph nodes, tumor size <5 cm, ulcerating macroscopic appearance, and curative surgical attempt. The independent prognostic factors on multivariate analysis were T stage and lymph node involvement. Conclusion: The overall T and N stages are the most important determining factor for survival in Omani Arab patients. More efforts need to be made for the early detection of gastric cancer in developing countries such as Oman, while continuing to employ the standard surgical and medical treatments.

Keywords:
Gastric cancer, Stomach
1.
Roukos DH: Current status and future perspectives in gastric cancer management. Cancer Treat Rev 2000;26:243–255.
2.
Cancer Incidence in Oman. Ministry of Health, Sultanate of Oman, 2002, pp 28–31.
3.
Tsugane S: Salt, salted food intake, and risk of gastric cancer: epidemiologic evidence. Cancer Sci 2005;96:1–6.
4.
Gonzalez CA: Vegetable, fruit and cereal consumption and gastric cancer risk. IARC Sci Publ 2002;156:79–83.
5.
Kelley JR, Duggan JM: Gastric cancer epidemiology and risk factors. J Clin Epidemiol 2003;56:1–9.
6.
Nishimoto IN, Hamada GS, Kowalski LP, et al: Risk factors for stomach cancer in Brazil. I. A case-control study among non-Japanese Brazilians in Sao Paulo. Jpn J Clin Oncol 2002;32:277–283.
7.
Gamboa-Dominguez A, Dominguez-Fonseca C, Chavarri-Guerra Y, et al: E-cadherin expression in sporadic gastric cancer from Mexico: exon 8 and 9 deletions are infrequent events associated with poor survival. Hum Pathol 2005;36:29–35.
8.
Troost E, Hold GL, Smith MG, et al: The role of interleukin-1beta and other potential genetic markers as indicators of gastric cancer risk. Can J Gastroenterol 2003;17(suppl B):8B–12B.
9.
Yao JC, Tseng JF, Worah S, et al: Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution’s experience over 15 years. J Clin Oncol 2005;23:3094–3103.
10.
Gill S, Shah A, Le N, et al: Asian ethnicity-related differences in gastric cancer presentation and outcome among patients treated at a Canadian cancer center. J Clin Oncol 2003;21:2070–2076.
11.
Verdecchia A, Mariotto A, Gatta G, et al: Comparison of stomach cancer incidence and survival in four continents. Eur J Cancer 2003;39:1603–1609.
12.
Adachi Y, Yasuda K, Inomata M, et al: Pathology and prognosis of gastric carcinoma: well versus poorly differentiated type. Cancer 2000;89:1418–1424.
13.
Giuliani A, Caporale A, Di Bari M, et al: Maximum gastric cancer diameter as a prognostic indicator: univariate and multivariate analysis. J Exp Clin Cancer Res 2003;22:531–538.
14.
Hassan HA, Sharma VK, Raufman JP: Changing trends in gastric carcinoma at a university medical center: a twelve-year retrospective analysis. J Clin Gastroenterol 2001;32:37–40.
15.
Hundahl SA, Phillips JL, Menck HR: The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: Fifth Edition American Joint Committee on Cancer staging, proximal disease, and the ‘different disease’ hypothesis. Cancer 2000;88:921–932.
16.
Kunisaki C, Shimada H, Takahashi M, et al: Prognostic factors in early gastric cancer. Hepatogastroenterology 2001;48:294–298.
17.
Skoropad V, Berdov B, Zagrebin V: Clinicopathological features and outcome of surgical treatment of 149 patients with early (pT1) gastric cancer. Onkologie 2005;28:247–252.
18.
Macdonald JS, Smalley SR, Benedetti J, et al: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725–730.
19.
Sasako M: Principles of surgical treatment for curable gastric cancer. J Clin Oncol 2003;21:274s–275s.
20.
Lauren P: The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand 1965;64:31–49.
21.
Greene FLP, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M: AJCC Cancer Staging Handbook. Berlin, Springer, 2002.
22.
Nishi M, Omori Y, Miwa K: Japanese Classification of Gastric Carcinoma. Tokyo, Kanehara, 1995.
23.
Koong HN, Chan HS, Nambiar R, et al: Gastric cancers in Singapore: poor prognosis arising from late presentation. Aust NZ J Surg 1996;66:813–815.
24.
Yokota T, Ishiyama S, Saito T, et al: Lymph node metastasis as a significant prognostic factor in gastric cancer: a multiple logistic regression analysis. Scand J Gastroenterol 2004;39:380–384.
25.
Vaquerano J, Esemuede N, Odocha O, Leffall LD: Gastric carcinoma in African Americans: a 10 year single center analysis. In Vivo 1996;10:233–235.
26.
Dicken BJ, Saunders LD, Jhangri GS, et al: Gastric cancer: establishing predictors of biologic behavior with use of population-based data. Ann Surg Oncol 2004;11:629–635.
27.
Thong-Ngam D, Tangkijvanich P, Mahachai V, Kullavanijaya P: Current status of gastric cancer in Thai patients. J Med Assoc Thai 2001;84:475–482.
28.
Kandasami P, Tan WJ, Norain K: Gastric cancer in Malaysia: the need for early diagnosis. Med J Malaysia 2003;58:758–762.
29.
Noguchi Y, Yoshikawa T, Tsuburaya A, et al: Is gastric carcinoma different between Japan and the United States? Cancer 2000;89:2237–2246.
30.
Tsubono Y, Hisamichi S: Screening for gastric cancer in Japan. Gastric Cancer 2000;3:9–18.
31.
Nomura E, Tsukuma H, Ajiki W, Oshima A: Population-based study of relationship between hospital surgical volume and 5-year survival of stomach cancer patients in Osaka, Japan. Cancer Sci 2003;94:998–1002.
32.
Bonenkamp JJ, van de Velde CJ, Kampschoer GH, et al: Comparison of factors influencing the prognosis of Japanese, German, and Dutch gastric cancer patients. World J Surg 1993;17:410–415.
33.
Inoue K, Nakane Y, Michiura T, et al: Trends in long-term survival following surgery for gastric cancer: a single institution experience. Oncol Rep 2004;11:459–464.
34.
Stemmermann GN, Fenoglio-Preiser C: Gastric carcinoma distal to the cardia: a review of the epidemiological pathology of the precursors to a preventable cancer. Pathology 2002;34:494–503.
35.
Yao JC, Schnirer II, Reddy S, et al: Effects of sex and racial/ethnic group on the pattern of gastric cancer localization. Gastric Cancer 2002;5:208–212.
36.
Zhan YQ, Sun XW, Li W, et al: Multivariate prognostic analysis in gastric carcinoma patients after radical operation. Ai Zheng 2005;24:596–599.
37.
Kim DY, Joo JK, Ryu SY, et al: Clinicopathological characteristics of patients with proximal third gastric carcinoma. Acta Chir Belg 2004;104:677–682.
38.
Inoue K, Nakane Y, Michiura T, et al: Histopathological grading does not affect survival after R0 surgery for gastric cancer. Eur J Surg Oncol 2002;28:633–636.
39.
Hundahl SA, Macdonald JS, Benedetti J, Fitzsimmons T: Surgical treatment variation in a prospective, randomized trial of chemoradiotherapy in gastric cancer: the effect of undertreatment. Ann Surg Oncol 2002;9:278–286.
40.
Hartgrink HH, van de Velde CJH, Putter H, et al: Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch Gastric Cancer Group trial. J Clin Oncol 2004;22:2069–2077.
41.
Kappas AM, Fatouros M, Roukos DH: Is it time to change surgical strategy for gastric cancer in the United States? Ann Surg Oncol 2004;11:727–730.
42.
Shiu MH, Moore E, Sanders M, et al: Influence of the extent of resection on survival after curative treatment of gastric carcinoma. A retrospective multivariate analysis. Arch Surg 1987;122:1347–1351.
43.
Hayes N, Ng EK, Raimes SA, et al: Total gastrectomy with extended lymphadenectomy for ‘curable’ stomach cancer: experience in a non-Japanese Asian center. J Am Coll Surg 1999;188:27–32.
44.
Carboni F, Lepiane P, Santoro R, et al: Extended multiorgan resection for T4 gastric carcinoma: 25-year experience. J Surg Oncol 2005;90:95–100.
45.
Kobayashi A, Nakagohri T, Konishi M, et al: Aggressive surgical treatment for T4 gastric cancer. J Gastrointest Surg 2004;8:464–470.
46.
Bonenkamp JJ, Hermans J, Sasako M, et al: Extended lymph-node dissection for gastric cancer. N Engl J Med 1999;340:908–914.
47.
Cuschieri A, Weeden S, Fielding J, et al: Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J Cancer 1999;79:1522–1530.
48.
National Comprehensive Cancer Network Web site. http://www.nccn.org/.
49.
Kattan MW, Karpeh MS, Mazumdar M, et al: Postoperative nomogram for disease-specific survival after an R0 resection for gastric carcinoma. J Clin Oncol 2003;21:3647–3650.
50.
Fujii M, Sasaki J, Nakajima T: State of the art in the treatment of gastric cancer: from the 71st Japanese Gastric Cancer Congress. Gastric Cancer 1999;2:151–157.
51.
Macdonald JS: Adjuvant therapy for gastric cancer. Semin Oncol 2003;30:19–25.
52.
Macdonald JS: Treatment of localized gastric cancer. Semin Oncol 2004;31:566–573.
53.
Van Cutsem E: The treatment of advanced gastric cancer: new findings on the activity of the taxanes. Oncologist 2004;9:9–15.
54.
Oluwasola AO, Ogunbiyi JO: Gastric cancer: aetiological, clinicopathological and management patterns in Nigeria. Niger J Med 2003;12:177–186.
© 2006 S. Karger AG, Basel
2006
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.